Beta-Defensin 2

HBD-2 disrupts bacterial membranes through its cationic beta-sheet structure with three disulfide bonds (trans configuration, distinguishing beta from alpha-defensins). The electrostatic targeting to anionic lipopolysaccharide (Gram-negatives) and lipoteichoic acid (Gram-positives) is followed by membrane integration and pore formation. The activity is partially salt-dependent but remains effective at mucosal surface ion concentrations, unlike some other defensins that lose activity at physiological salt.

HBD-2 functions as a chemoattractant for immature dendritic cells and memory T cells by binding the chemokine receptor CCR6. This recruits adaptive immune effectors to sites of infection or barrier breach, linking the immediate antimicrobial action of HBD-2 to downstream T cell-mediated immunity. This dual antimicrobial-chemokine function is shared with other defensins and positions the defensin family as key communication molecules between innate and adaptive immunity.

HBD-2 is significantly upregulated in psoriatic skin lesions (>100-fold vs normal) but deficient in atopic dermatitis lesions. This differential expression explains why atopic dermatitis patients have increased susceptibility to S. aureus and HSV superinfections while psoriasis patients do not. The inverse HBD-2 relationship between these diseases has implications for understanding immune dysregulation and potential therapeutic approaches targeting defensin induction in atopic skin.

Recombinant HBD-2 has been investigated as a topical therapeutic for ulcerative colitis, where HBD-2 expression is deficient in non-inflamed mucosa. Rectal administration of HBD-2 in animal models of colitis reduces mucosal inflammation and bacterial translocation. This represents a potential "defensin replacement" therapy concept. Clinical trials by Lytone Inc. showed some promise in early Phase 2 for ulcerative colitis, though results are not fully published.